Clinical trials: Pregnancy
Bladder Cancer, Neoplasms
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
A prospective, open label, modified 3+3 dose escalation study. This dose-escalation study is designed to carefully assess the safety of successive cohorts of patients (3 patients/cohort), each cohort treated with a fixed dose of…
- Conditions
- Bladder Cancer, Neoplasms, Urinary Bladder Diseases, Urologic Diseases
- Trial name
- NCT02307487
- Testing
- 120 mg MMC in 90ml gel, 140 mg MMC in 90ml gel, 160 mg MMC in 90ml gel
- Where
- 2 sites in Israel
- Volunteers
- 14 people
- Sponsor
- UroGen Pharma Ltd.
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease.
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Trial name
- NCT04235621
- Testing
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Where
- 18 sites in United States
- Volunteers
- 20 people
- Sponsor
- Goldfinch Bio, Inc.
Systemic Lupus Erythematosus
The Anifrolumab PRIM Program
Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program
- Trial name
- PRIM (NCT06795893)
- Testing
- Anifrolumab
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Cardiovascular Risk, Chronic Kidney Disease
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
The purpose of this clinical study is to find out what happens to kidney and heart health during treatment with a medicine called semaglutide, which is given as an injection under the skin.
- Trial name
- NCT07900438
- Testing
- Semaglutide
- Where
- 26 sites in China
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Autosomal Dominant Polycystic Kidney Disease
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of the trial was to determine the short-term effects of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) at various levels of renal function.
- Trial name
- NCT01336972
- Testing
- Tolvaptan
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Urothelial Carcinoma
Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma
Urothelial carcinoma (UC) is the most common malignancy of the urinary system. Hematuria is a significant clinical manifestation of UC, often diagnosed through invasive procedures.
- Trial name
- UMT-UC (NCT06912672)
- Testing
- Evaluate the diagnostic performance of EPIPROBE TAGMe DNA Methylation Detection Kit for Urothelial Cancer
- Volunteers
- 1,500 people
- Sponsor
- Shanghai Epiprobe Biotechnology Co., Ltd.
Underactive Bladder
A Study of ASP8302 in Participants With Underactive Bladder
The study objectives of this study are to evaluate the efficacy of ASP8302 compared with placebo in participants with underactive bladder (UAB), to investigate the safety and tolerability of ASP8302 compared with placebo in…
- Trial name
- NCT03702777
- Testing
- ASP8302
- Where
- 29 sites in Germany, Japan and 4 more
- Volunteers
- 135 people
- Sponsor
- Astellas Pharma Europe B.V.
Bladder Cancer, Transitional Cell Bladder Cancer
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth)…
- Conditions
- Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer
- Trial name
- NCT00661609
- Testing
- AZD4877
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Diphtheria-Tetanus-acellular Pertussis Vaccines
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women
The purpose of this study is to assess the immunogenicity and safety of Boostrix™ when compared to a placebo given during 27-36 weeks of gestation in healthy women aged 18-45 years.
- Trial name
- NCT02377349
- Testing
- Boostrix™
- Where
- 35 sites in Australia, Canada and 4 more
- Volunteers
- 688 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Cell Cancer
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell…
- Trial name
- NCT02684006
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
- Where
- 270 sites in United States, Australia and 19 more
- Volunteers
- 886 people
- Sponsor
- Pfizer
Endometrial Cancer
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory or…
- Trial name
- NCT00003821
- Testing
- aminopterin
- Where
- 6 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Ovarian Cancer, Prostate Cancer
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites.
- Trial name
- NCT04560452
- Where
- 37 sites in China
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Chronic Kidney Diseases, Hemodialysis
Must Cannulation Technique of Vascular Access in Patients Undergoing Haemodialysis: Contributions for a Safe Nursing Intervention
The aims of this study are to: Determine the AVF (arteriovenous fistula) survival of patients submitted to MuST compared to those submitted to RL (rope-ladder).
- Conditions
- Chronic Kidney Diseases, Hemodialysis, Vascular Access Complication, Hemodialysis Access Failure
- Trial name
- MuST (NCT05081648)
- Testing
- CT MuST, Rope-ladder cannulation technique
- Where
- 3 sites in Portugal
- Volunteers
- 101 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Recurrent Bladder Cancer
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
- Trial name
- FPA144 (NCT03801278)
- Testing
- FPA144
- Sponsor
- Five Prime Therapeutics, Inc.
Renal Impairment
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function
Renal excretion is a minor elimination route of telotristat etiprate. So this trial is intended to assess the drug behaviour in subjects with decreased renal function.
- Trial name
- NCT03442725
- Testing
- Telotristat etiprate
- Where
- 4 sites in Belgium, Germany and 2 more
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ipsen
Endometrial Cancer, Ovarian Cancer
PRO1107 in Patients With Advanced Solid Tumors
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors.
- Conditions
- Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer
- Trial name
- NCT06171789
- Testing
- GEN1107
- Where
- 7 sites in United States, China
- Volunteers
- 33 people
- Sponsor
- Genmab
Congestive Heart Failure, Chronic Kidney Diseases
Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects
The study will evaluate the within-subject variability of 20mg ER torsemide as compared to 20mg IR torsemide (Demadex) in fully replicate double-crossover trial in healthy volunteers, who are consuming a high-salt diet (300…
- Trial name
- NCT03214874
- Testing
- Demadex 20mg Tablet, ER Torsemide 20mg Tablet
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Advanced Solid Tumor, CDKN2A
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
This is an open-label, single-arm, Phase 1b/2 study designed to evaluate the safety, tolerability, and preliminary efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors with confirmed…
- Conditions
- Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder
- Trial name
- NCT06090318
- Testing
- Milademetan, Atezolizumab
- Sponsor
- Rain Oncology Inc
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.